[Current status and problems of anticancer drug-induced lung injuries].
Some large-scale clinical investigations on gefitinib-induced lung injury have been performed,which have much new information about anticancer drug-induced lung injuries and indicated significant problems in the development of new anticancer drugs. Analysis of gefitinib-induced lung injury revealed varying patterns of clinical features, ethnic differences in onset, risk factors for development and diagnostic difficulties in anticancer drug-induced lung injuries. Furthermore, we realized again underlying problems in the process of developing new anticancer drugs and the importance of post-marketing surveillance. We must elucidate the mechanism of anticancer drug-induced lung injuries to manage them effectively.
Kudoh
Shoji
S
Fourth Dept. of Internal Medicine, Nippon Medical School.
Yoshimura
Akinobu
A
D000970:Antineoplastic Agents / Q000009:adverse effects*; D003937:Diagnosis, Differential; D000077156:Gefitinib; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis; D009369:Neoplasms / Q000188:drug therapy*; D011358:Product Surveillance, Postmarketing; D011799:Quinazolines / Q000009:adverse effects*; D012307:Risk Factors
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib